SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is plunging amid concerns about rising AI costs and increasing debt, overshadowing otherwise strong cloud growth and backlog. The community is actively debating whether this dip is an overreaction or a sign of deeper problems with Oracle's AI strategy, while some see a buying opportunity, others fear further declines.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending as traders anticipate news from an upcoming investor conference, with discussions focusing on potential share buybacks and the company's transition into AI infrastructure. The stock's low float and recent price action have fueled speculation of a potential short squeeze, though strong resistance around a key price level has created a battle between bulls and bears. Community members are actively discussing strategies to break through resistance and maximize potential gains.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly after positive data in prostate cancer trials, while also citing undervaluation. The community is actively discussing the possibility of a short squeeze given the high short interest. Some also speculate about potential partnerships and acquisitions in the near future, especially with a key presentation approaching.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

BTTC is trending due to positive news around its DAT+ framework, sparking discussions about its potential in the digital asset space. Community members are actively debating the possibility of a significant squeeze, with some expressing concerns about trading halts and market manipulation. The stock's volatile price action and association with the crypto sector are also fueling the conversation.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending as investors debate whether it's a buying opportunity after hitting new lows, driven by concerns about competition and tax-loss harvesting. Community discussions revolve around the potential for a turnaround, the impact of Amazon's growing presence, and frustrations with the company's leadership amidst a significant year-to-date decline. Despite strong financials and AI investments, the stock struggles to gain momentum, leaving investors divided between those anticipating a rebound and those fearing further downside.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending due to its derivatives arm, Gemini Titan, securing a CFTC designated contract market license, allowing them to launch regulated prediction markets in the U.S. The community sees this as a potential long-term bullish reversal and a catalyst for significant valuation growth, with comparisons being drawn to Kalshi's valuation.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL is trending due to a recently announced national retail distribution agreement with Walmart, sparking community excitement about increased market reach. Discussions revolve around the potential for a short squeeze, given the stock's low float and high short interest. Some traders are closely watching volume and key price levels, while others express caution about potential volatility.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending following positive Q3 earnings, guidance, and a new contract with the U.S. Navy, driving discussions about its growth potential in the space and defense sectors. The community is focused on the company's strong financials and backlog, and its potential as a long-term investment, with some eyeing a breakout towards $20. The recent surge is also attributed to increased interest in space data and infrastructure, with some comparing it to a mini SpaceX.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is experiencing volatility as traders react to a mix of news, including a report of declining funded customers in November and Cantor Fitzgerald's updated overweight rating with a price target of 155. Community discussions revolve around the dip as a buying opportunity versus concerns about trading volumes and market manipulation. The stock's correlation with Bitcoin's price movement and the broader market adds to the uncertainty, despite some anticipating a potential Santa Claus rally.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss its potential role in the AI landscape, particularly within data centers. Community members are highlighting the company's photonics technology, suggesting it could disrupt the AI sector by offering greater efficiency. The stock is gaining attention as discussions around its valuation and potential to address the growing demands of AI infrastructure intensify.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The CEO said that the company received 50,000 orders for the pickup trucks incorporating its reintroduced Hemi V8 engine.&nbsp;</li><li>The company is also looking to relaunch the Jeep Cherokee to the end of December, featuring a a hybrid engine.</li><li>Filosa sees hybrid being one of the favorite powertrains in the U.S.</li></ul>Stellantis (STLA) CEO Antonio Filosa said on Thursday that the company envisions ‘highly sustainable’ demand growth with the launch of new engines and vehicle models as he seeks to claw back market share.The CEO said that the company received 50,000 orders for the pickup trucks incorporating its reintroduced Hemi V8 engine.Stellantis had previously phased out the engine and reintroduced it in pickup trucks in the third quarter (Q3). The CEO said at the Goldman Sachs Industrial &amp; Auto Conference on Thursday that the company delivered 10,000 v8-equipped Hemi engine RAM vehicles in Q3 and expects to ship another 20,000 in the fourth quarter.<h2 class="st-heading-2">Other Launches</h2>The company is also looking to relaunch the Jeep Cherokee by the end of December, featuring &nbsp;a hybrid engine. It is also eyeing the launch of a new Dodge Charger with an internal combustion engine.“So we are launching hybrid because we truly believe that hybrid is going to be one of the favorite powertrains in the U.S.,” Filosa said on Thursday. The company expects its sequence of product launches to spark volume growth that is “highly sustainable and progressively better quarter by quarter.”“Through the end of November, we are on track on our guidance,” Filosa said about the company’s profitability expectations. The CEO also highlighted that the company’s execution is improving with more product launches following promised timelines.<h2 class="st-heading-2">Tariff Impact</h2>The CEO highlighted that U.S. tariffs are getting stable and the company is looking to offset the impact of the Trump administration’s tariffs by onshoring production.In October, Stellantis committed $13 billion to expand its US operations over the next four years. The investment will support the launch of five new vehicles, the company then said.<h2 class="st-heading-2">Filosa Attempts Major Pivot</h2>Stellantis <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-selects-antonio-filosa-as-new-ceo/ch0oL02Rbs3">appointed</a> Filosa as CEO in May after its previous chief executive, Carlos Tavares, stepped down in December 2024.In October, the company reported a 13% growth in Q3 revenue to €37.2 billion ($43.35 billion) owing to a 13% growth in consolidated shipments to 1.3 million units.“As we continue to implement important strategic changes in order to provide our customers with greater freedom of choice, we have seen positive sequential progress and solid year-over-year performance in Q3, marked by the return of top-line growth. This is encouraging and we are continuing to build on these gains,” Filosa then said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">Stellantis</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.The stock is down by 9% this year and by about 7% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pepsico-close-to-striking-settlement-with-activist-giant-elliott-after-4-billion-push-for-change/cLIi4iXREj1">PepsiCo Is Close To Striking A Settlement With Activist Giant Elliott After Its $4B Push For Change</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

New Ram vehicles sit on a Dodge Chrysler-Jeep Ram dealership's lot on October 03, 2023 in Miami, Florida. (Photo by Joe Raedle/Getty Images)

Stellantis CEO Says New Engine, Vehicle Models Will Drive ‘Progressively Better’ Demand 

Filosa said that the company is on track on its full year guidance through the end of November. 

Equity

Filosa said that the company is on track on its full year guidance through the end of November. 


<ul class="summary-bullets"><li>In the three months through the end of September, Li delivered 93,211 vehicles, representing a 39.0% year-over-year decrease.</li><li>Adjusted net loss per American Depositary Share (ADS) was RMB0.36 in Q3, compared to earnings of RMB3.63 per ADS reported in the corresponding quarter of 2024.&nbsp;</li><li>For the fourth quarter, the company expects to deliver between 100,000 and 110,000 vehicles, representing a year-over-year decrease of 37.0% to 30.7%.</li></ul>Li Auto (LI) CEO Xiang Li stated on Wednesday that several challenges impacted the company over the three months through the end of September, including supply chain constraints, product lifecycle challenges, PR challenges, and changing policies, resulting in an unexpected loss.“All these factors have had a negative impact on our operations and deliveries,” he said. In the three months through the end of September, Li <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lixiang.com/news-releases/news-release-details/li-auto-inc-announces-unaudited-third-quarter-2025-financial">delivered</a> 93,211 vehicles, representing a 39.0% year-over-year decrease.<h2 class="st-heading-2">Q3 Earnings</h2>Total revenues in the quarter came in at RMB27.4 billion ($3.87 billion), down 36.2% from RMB42.9 billion in the third quarter of 2024, but above the analyst estimate of RMB26.49 billion.Adjusted net loss per American Depositary Share (ADS) was RMB0.36 in the quarter, compared to earnings of RMB3.63 per ADS reported in the third quarter of 2024. Analysts on average had expected the company to report earnings of RMB0.64 per share.For the fourth quarter, the company expects to deliver between 100,000 and 110,000 vehicles, representing a year-over-year decrease of 37.0% to 30.7%, amid subdued demand and strong competition.Total revenue, meanwhile, is expected to be between RMB26.5 billion and RMB29.2 billion, representing a year-over-year decrease of 40.1% to 34.2%. This is below the analyst estimate of RMB36.99 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/LI">LI shares</a> traded 3% higher at the time of writing on Wednesday morning. On Stocktwits, retail sentiment around LI stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user expressed surprise at the stock rising.<stembedurl>https://stocktwits.com/Kingofsting/message/637515375</stembedurl>Another highlighted that the positive stock reaction reflects how beaten down the shares already were.<stembedurl>https://stocktwits.com/topstockalerts/message/637526362</stembedurl>LI stock is down by 22% this year and by about 14% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/arrowhead-pharmaceuticals-stock-jumps-after-morgan-stanley-hikes-price-target/cL53te9REWo">Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: RMB1= $0.14

Employees adjust new energy vehicles at the workshop of Li Auto Changzhou Manufacturing Base on December 10, 2024 in Changzhou, Jiangsu Province of China. (Photo by Chen Wei/VCG via Getty Images)

Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop

CEO Xiang Li highlighted challenges pertaining to the supply chain and product lifecycle, among others. 

<ul class="summary-bullets"><li>Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said.</li><li>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.&nbsp;</li><li>The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.</li></ul> Novo Nordisk (NVO) on Tuesday said that a mid-stage trial evaluating Amycretin in people with type 2 diabetes yielded positive outcomes in both weight loss and reduction in average blood sugar levels.NVO shares traded 3% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Study Outcomes</h2>Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks, as compared to 2.6% in patients treated with placebo, and demonstrated statistically significant reductions in average blood sugar levels, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/25/3194155/0/en/Novo-Nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-HbA1c-reduction-in-type-2-diabetes.html">said</a>.The trial investigated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous Amycretin and once-daily oral amycretin compared with placebo in 448 people with type 2 diabetes inadequately controlled on metformin. About 40% of the study participants also used a class of drugs known as SGLT2 inhibitors to manage their diabetes before joining the study.Amycretin belongs to the class of drugs known as GLP-1s, used to treat diabetes and obesity, similar to Novo’s blockbuster drugs Wegovy and Ozempic. Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said. The common side effects were gastrointestinal, and the vast majority were mild to moderate in severity, the company added.<h2 class="st-heading-2">Plans Ahead</h2>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.Chief Scientific Officer Martin Holst Lange noted that this is the first time Amycretin has been evaluated in this population and added that the company is planning to test the GLP-1 compound across multiple indications starting next year.The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.The company said on Monday that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression, and it is subsequently discontinuing them.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by 48% this year and by about 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/autl-stock-soars-pre-market-on-position-recommendation-for-cell-therapy-targeting-cancer-in-uk/cL52LfPREXA">AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study

The trial was investigating the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared to placebo in 448 people with type 2 diabetes. 

<ul class="summary-bullets"><li>The company’s second-quarter revenue rose 5% to RMB 247.80 billion, compared with analysts’ expectations of RMB 243.2 billion, according to data compiled by Fiscal AI.&nbsp;</li><li>Alibaba said that it was seeing accelerated adoption of its AI products across a broad range of enterprise customers, with a growing focus on value-added applications, including coding assistants.</li><li>The company said that its quick commerce business has substantially improved its unit economics since September.</li></ul>Alibaba Group Holding (BABA) shares rose nearly 4% in premarket trading on Tuesday as investor optimism gathered momentum after the company’s upbeat second-quarter revenue and CEO Eddie Wu’s remarks on robust AI demand accelerating the Cloud Intelligence Group business.“With our significant strategic investments in these areas, our two core businesses of AI + Cloud and consumption continued to deliver strong growth this quarter,” Wu said.He added that Cloud Intelligence Group's revenue was up 34% for the quarter ended September 30, and AI-related product revenue achieved triple-digit year-over-year growth for the ninth consecutive quarter.The company’s second-quarter revenue rose 5% to RMB&nbsp;247.80 billion ($34.89 billion), compared with analysts’ expectations of RMB 243.2 billion, according to data compiled by Fiscal AI.Alibaba’s adjusted net income was RMB 10.35 billion, compared to RMB 36.52 billion in the same quarter of 2024.<h2 class="st-heading-2">BABA CFO View</h2>CFO Toby Xu said that Alibaba’s core businesses continued to deliver revenue growth, with AI revenue contributing to an expanding share of its cloud revenues from external customers, and customer management revenue being up 10%.“We are re-investing our profits and free cash flow for the future, while near-term profitability is expected to fluctuate. Over the past four quarters, we have deployed approximately RMB120 billion in capital expenditure toward AI and cloud infrastructure,” said Xu.Alibaba said that it was seeing accelerated adoption of its AI products across a broad range of enterprise customers, with a growing focus on value-added applications, including coding assistants. “We will continue to invest in anticipation of customer growth and technology innovation, including AI products and services, to increase adoption of AI infrastructure cloud and strengthen our market leadership,” Alibaba said.<h2 class="st-heading-2">E-commerce Growth</h2>Alibaba said its quick commerce business has substantially improved unit economics since September, driven by higher fulfillment logistics efficiency, strong customer retention, and rising average order value.“As part of our strategy to generate synergies between quick commerce and the rest of Alibaba’s ecosystem, we accelerated the onboarding of Tmall brands to our quick commerce channel to expand product offering and meet consumer needs for on-demand delivery,” the company said.Alibaba onboarded offline stores from nearly 3,500 Tmall brands to the quick commerce business as of October 31, 2025.<h2 class="st-heading-2">What Is Retail Thinking?</h2>Alibaba’s ticker was the top third-trending one on Stocktwits. Retail sentiment on Alibaba jumped to ‘bullish’ territory from ‘extremely bearish’ a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/BABA">Shares of Alibaba</a> have gained nearly 90% this year.&nbsp;RMB 1 = $0.14For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amex-gbt-reportedly-mulls-potential-sale/cL52QdHREXS">Amex GBT Reportedly Mulls Potential Sale, Retail Turns Bullish</a>

The Alibaba booth at the 3rd China International Supply Chain Expo, pictured on 18 August 2025. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BABA Stock Rises Pre-Market As AI-Driven Cloud Growth Drives Revenue Beat

CEO Eddie Wu said Cloud Intelligence Group's revenue rose 34% in the quarter ended September 30.

<ul class="summary-bullets"><li>Semaglutide is the active ingredient in Novo’s blockbuster drugs Wegovy and Ozempic.&nbsp;</li><li>The company said it decided to test the drug in Alzheimer’s disease based on real-world evidence and preclinical models.</li><li>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease.</li></ul>Novo Nordisk (NVO) on Monday said that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression.Shares of the company slumped 11% in the pre-market session at the time of writingSemaglutide is the active ingredient in Novo’s blockbuster weight-loss drug Wegovy. The company said that it decided to test the drug in Alzheimer’s based on real-world evidence studies, pre-clinical models, as well as post-hoc analyses from diabetes and obesity trials. The compound, belonging to the category known as GLP-1 drugs, is marketed as Ozempic and Rybelsus for the treatment of type 2 diabetes as well.<h2 class="st-heading-2">Trial Outcomes</h2>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193328/0/en/Novo-Nordisk-A-S-Evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-Alzheimer-s-disease-progression.html">said</a>. The two trials enrolled a total of 3,808 adults and were aimed at evaluating the efficacy and safety of oral Semaglutide compared to placebo on top of standard of care in early-stage symptomatic Alzheimer’s disease.Alzheimer’s is a leading cause of memory loss or dementia. It is a progressive disease where symptoms gradually worsen over time. Semaglutide appears to have a safe and well-tolerated profile in the studies with patients aged 55-85 suffering from mild cognitive impairment or mild dementia due to Alzheimer’s disease, Novo noted.The company said that it is discontinuing the trials. However, the data generated will continue to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities, it added. The data from the trials will also be presented at future conferences, the company said.<h2 class="st-heading-2">Semaglutide And Its Many Indications</h2>Semaglutide is Novo's biggest asset. In the nine months through the end of September, the company reported sales of DKK 95.264 billion ($14.721.52 billion) from Ozempic, DKK 16.790 billion from Rybelsus and DKK 57.242 billion from Wegovy, togetherly accounting for about 74% of the company’s overall sales in the period.&nbsp;An approval in Alzheimer’s could have helped the company ramp revenue from the compound as its rivalry with American GLP-1 drugmaker Eli Lilly intensifies.&nbsp;The company’s drop in share price prompted a change in CEO earlier this year and layoffs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 45% this year and by 54% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-holds-86000-crypto-market-back-above-3-trillion-xrp-doge-gain/cL5bex0REQP">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: DKK1= $0.15

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies

The company said that it is discontinuing the trials.

<ul class="summary-bullets"><li>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.</li><li>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five.</li><li>As per the agency, not all cases automatically qualify for compensation, but instead, each claim will be assessed individually.</li></ul>Four patients taking Novo Nordisk’s (NVO) weight loss drugs have been granted compensation in Denmark after they developed an adverse reaction that affected their eyes.The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://patienterstatningen.dk/presse-og-nyheder/nyheder/2025/nov/de-foerste-patienter-faar-erstatning-for-alvorlig-oejensygdom-efter-wegovy-og-ozempic">said</a> on Friday. If it is proved that the eye disease is to blame for the patients not being able to do their jobs to the same extent as before, they will be entitled to compensation for loss of earning capacity, the authority said.<h2 class="st-heading-2">Cases In Question</h2>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.NAION, or non-arteritic anterior ischemic optic neuropathy, is a medical condition causing sudden, painless vision loss due to a lack of blood flow to the optic nerve. There is no cure for the condition, which can cause blurry or worsening vision, reduced color vision, and optic disc swelling.<h2 class="st-heading-2">Compensation Not Guaranteed</h2>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five. According to the agency, not all cases automatically qualify for compensation; each claim will be assessed individually to determine whether compensation is warranted.“NAION is a serious disease that causes permanent and incurable damage to vision. It is also a very complex case to assess because it is a new medicine and the patients are already in the risk group for getting NAION. Our task is to give patients a thorough and well-thought-out decision," director of Patient Compensation, Karen-Inger Bast, said. &nbsp;The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) considers NAION to be a rare side effect of Wegovy, Ozempic, and Rybelsus.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> traded 1% lower on Friday morning at the time of writing. On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.NVO stock is down 45% this year and by about 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-etfs-hit-record-outflows-average-investor-now-in-the-red/cLPMoktREOm">Bitcoin ETFs Hit Record Monthly Outflows In November – Average Investor Now in the Red, Says Analyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic

The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation said on Friday.

<ul class="summary-bullets"><li>After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified in the patient who died, the FDA said.&nbsp;</li><li>The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma.</li><li>The agency noted that neutralizing antibodies were not reported in clinical trials.</li></ul>The U.S. Food and Drug Administration (FDA) said on Friday that it is investigating the death of a patient treated with Adzynma.Adzynma, a man-made enzyme therapy manufactured by Takeda Pharmaceuticals (TAK), is approved for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman syndrome. It is a rare inherited disorder characterized by a severe deficiency of the ADAMTS13 enzyme.The death of a pediatric cTTP patient appears to be related to Adzynma, the FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-death-due-neutralizing-antibodies-adamts13-following-adzynma-treatment-congenital">said</a>.<h2 class="st-heading-2">Findings And Further Probe</h2>Before starting Adzynma treatment, the patient had severe allergic reactions to fresh frozen plasma, the FDA noted. After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified.However, the agency also noted that current assays cannot differentiate the neutralizing antibodies to man-made enzyme therapy from the neutralizing antibodies to the body’s own enzymes. The agency also added that it has received other reports of neutralizing antibodies in patients treated with the drug since approval.The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma. The agency noted that neutralizing antibodies were not reported in clinical trials and that the current labeling does not include the risk of serious and fatal outcomes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TAK stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/TAK">TAK stock</a> has gained 8% this year and about 7% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-obesity-drug-patients-granted-compensation-in-denmark-over-rare-eye-disease-linked-to-wegovy-ozempic/cLPMqfwREOY">Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Takeda Pharmaceutical Company, building exterior with company sign, 500 Kendall Street, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies

 The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 

<ul class="summary-bullets"><li>The outcome was unsurprising as Novo Nordisk Foundation controls 77% of the votes at the Novo Nordisk Annual General Meeting.</li><li>Sorensen said he intends to stay on in the role for a maximum of three years.</li></ul>Novo Nordisk (NVO) said on Friday that Lars Rebien Sørensen, the chair of its dominant shareholder, Novo Nordisk Foundation, has been elected as chair of the Board at the drugmaker, replacing Helge Lund.The outcome was unsurprising as Novo Nordisk Foundation controls 77% of votes at the Novo Nordisk Annual General Meeting through its investment company, Novo Holdings A/S. Sørensen was also previously the CEO of Novo from 2000 to 2016. &nbsp;<h2 class="st-heading-2">The New Chairman</h2>Sørensen, however, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916459">said</a> that he intends to hold the position only for a period of two to three years. “My mandate is very clear. I have two important tasks together with the Board: First, to support the CEO and the management in its transformation plans to regain its competitive leadership, and second, prepare the way for my successor,” he said.Novo named Mike Doustdar as CEO of the company in August after Lars Fruergaard Jørgensen stepped down in May. Jørgensen decided to step down as per a mutual agreement with the Novo Nordisk board. The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.Sorensen on Friday also said that he is looking to “strengthen the board with some qualifications,” with recent pharma or over-the-counter business experience. “We might see a future where our GLP-1 product is going in this direction,” he said, highlighting the company’s ambitions to make its drugs over-the-counter without prescription.Minority shareholders, including Norway’s sovereign wealth fund and CalSTRS, opposed Sorensen’s appointment. Proxy advisor ISS also urged investors to abstain, citing “limited transparency and accountability to minority shareholders.”<h2 class="st-heading-2">Other appointments</h2>Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.The new appointment comes amid Novo’s intense competition in the weight-loss drug market with its U.S. counterpart, Eli Lilly, and a dramatic board rupture last month, in which disagreements over governance principles between Novo’s board and the foundation prompted more than half of the supervisory board to resign.<a href="https://stocktwits.com/symbol/NVO">Shares of NVO</a> traded 2% lower by Thursday noon. On Stocktwits, retail sentiment around NVO rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism about the stock, citing the price-to-earnings valuation.<stembedurl>https://stocktwits.com/Bassfisher89/message/636229521</stembedurl>Another expressed hopes for the stock’s prospects.<stembedurl>https://stocktwits.com/Natetruu/message/636213210</stembedurl>NVO shares are down by 44% this year and by 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-eyes-reapplication-for-approval-of-muscle-atrophy-therapy-in-2026/cLPQ17HRE4q">Why Did Scholar Rock Soar 26% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Novo Nordisk Brings Back Former CEO To Lead Board

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 

<ul class="summary-bullets"><li>The new plant opened in North Carolina is Toyota’s eleventh in the U.S. and its only battery plant outside Japan.&nbsp;</li><li>The batteries made at the plant will power vehicles including the Camry HEV, Corolla Cross HEV, RAV4 HEV, and a yet-to-be-announced all-electric 3-row BEV.</li><li>The additional $10 billion investment will bring Toyota’s total investment in the U.S. to nearly $60 billion since the carmaker started operations in the country.</li></ul>Japanese automaker Toyota Motor (TM) announced on Wednesday that it will invest up to an additional $10 billion in the U.S. over the next five years, as it seeks to expand its operations in its key market.The additional investment will bring Toyota’s total investment in the U.S. to nearly $60 billion since the carmaker started operations in the country.<h2 class="st-heading-2">New Plant Kick Start</h2>The company on Wednesday also kick-started production at its all-new $14 billion battery plant in Liberty, North Carolina. The plant is Toyota’s eleventh in the U.S. and its only battery plant outside Japan.The 1,850-acre site is expected to create up to 5,100 new jobs and produce 30 GWh annually at full capacity, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://global.toyota/en/newsroom/corporate/43553969.html">stated.</a> It will serve as the development and production hub for lithium-ion batteries needed for Toyota’s electrified vehicles, with 14 battery production lines supporting hybrid electric vehicles (HEVs), battery electric vehicles (BEVs), and plug-in hybrid electric vehicles (PHEVs).The batteries made at the plant will power vehicles including the Camry HEV, Corolla Cross HEV, RAV4 HEV, and a yet-to-be-announced all-electric 3-row BEV. It currently ships HEV modules to both Toyota Kentucky and Mazda Toyota Manufacturing in Alabama, the company said.<h2 class="st-heading-2">Trump’s Push</h2>The investment announcement comes as President Trump is pushing for more investments in the country, including through the imposition of high tariffs on imported vehicles.“Go out and buy a Toyota,” Trump said last month in an address to U.S. troops aboard the USS George Washington at the Yokosuka Naval Base after the Japanese PM informed him that Toyota is planning a $10 billion investment.According to Toyota estimates, the company has sold more than 6.6 million hybrid, plug-in hybrid, fuel cell, and battery electric vehicles in the U.S. since 2000.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TM">TM stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.TM stock is up by 6% this year and by 18% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/uber-coo-says-robotaxi-tech-is-largely-ready-but-hardware-costs-are-still-too-high/cLPICXdREd7">Uber COO Says Robotaxi Tech Is Largely Ready But Hardware Costs Are Still Too High</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Commits Up To $10B Additional Investments In US Over Five Years

The company also kick-started production at its all-new $14 billion battery plant in Liberty, North Carolina, on Wednesday.

<ul class="summary-bullets"><li>The facility is part of the company’s commitment, earlier this year, to invest $23 billion in the U.S. over the next five years.&nbsp;</li><li>Novartis is now also planning two additional RLT manufacturing facilities in Florida and Texas.&nbsp;</li><li>The U.S. is one of Novartis’ priority geographies in addition to China, Germany, and Japan.</li></ul>Novartis (NVS) on Monday said that it has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, marking its third RLT manufacturing site in the country.The facility is part of the company’s commitment earlier this year to invest $23 billion in the U.S. over the next five years.<h2 class="st-heading-2">Goals Of The New Facility</h2>The new facility is designed to add capacity for radioligand therapy, meeting future demand, and enhance the company’s supply chain capabilities, Novartis <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-opens-new-radioligand-therapy-manufacturing-facility-california-part-23b-us-expansion-plan">stated.</a>Radioligand therapy is a targeted cancer treatment that combines a radioactive substance (radioisotope) with a cancer-targeting molecule (ligand). It is aimed at reducing damage to surrounding cells.However, each RLT dose is custom-made and time-sensitive, making proximity to treatment centers and transit hubs necessary for patient access. The new site will ensure access to patients across the western U.S., Alaska, and Hawaii, Novartis said.Commercial manufacturing at the facility is expected to begin once approval is granted by the U.S. Food and Drug Administration, the company added.<h2 class="st-heading-2">Future Expansion Plans</h2>Novartis is now also planning two additional RLT manufacturing facilities in Florida and Texas. &nbsp;In addition, it is also eyeing expansion of existing sites in Durham, North Carolina, Indianapolis, Indiana, and Millburn, New Jersey, and expects to establish a second global research and development hub in the U.S. in San Diego, California.The U.S. is one of Novartis’ priority geographies, alongside China, Germany, and Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.NVS stock is up 31% this year and approximately 20% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/grab-holdings-to-take-equity-interest-in-remote-driving-tech-startup/cLPcKrSRE2c">Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence

Commercial manufacturing at the facility is expected to begin once approval is granted by the U.S. Food and Drug Administration, the company added.

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

DFAX
Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DFAX News

DFAXDimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF